Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiotargeted gene therapy.

Donald J Buchsbaum1, Tandra R Chaudhuri, Kurt R Zinn

  • 1Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL 35294, USA. djb@uab.edu

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|January 18, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pan-RAS Inhibitors: Expanding Therapeutic Potential and Evading Resistance.

Cancers·2026
Same author

Jump-starting the T cell response in established tumors.

bioRxiv : the preprint server for biology·2026
Same author

A Scoping Review of the Challenges and Future Perspectives in the Use of Alpha-Emitters for Metastatic Ovarian Cancer.

Molecules (Basel, Switzerland)·2026
Same author

ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma.

bioRxiv : the preprint server for biology·2026
Same author

Use of Dual-Modality Antibody Imaging for Assessment of Lymph Node Metastases in Head and Neck Cancer.

Theranostics·2026
Same author

Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models.

Cancers·2025
Same journal

Overall Survival with [<sup>177</sup>Lu]Lu-PSMA-617 Versus [<sup>177</sup>Lu]Lu-PSMA I&T: A Propensity Score-Matched Real-World Analysis.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Toward a Biopsy-Free Diagnosis of Prostate Cancer: Potential of Combined <sup>18</sup>F-Flotufolastat PSMA PET and mpMRI.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

PSMA PET/CT-Targeted Biopsy in Men with Negative or Equivocal Multiparametric MRI and Exploratory Dynamic Total-Body PET: The FUPERMAN Study.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Erratum.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

Live from 2026 SNMMI Annual Meeting in Los Angeles!

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same journal

CAR T-Cell Therapy for Cancer: Updates and Challenges for Response Assessment.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
See all related articles

Radiotargeted gene therapy enhances cancer treatment by directing radioactive agents to tumors. This approach uses gene transfer to improve the accuracy and effectiveness of radionuclide delivery for targeted cancer therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiochemistry

Background:

  • Radiotargeted gene therapy aims to localize radionuclides at tumor sites.
  • Two strategies include inducing tumor cells to express specific receptors or transducing the sodium iodide symporter (NIS).

Purpose of the Study:

  • To evaluate the efficacy of radiotargeted gene therapy approaches for cancer treatment.
  • To explore the potential of gene transfer in enhancing radionuclide delivery to tumors.

Main Methods:

  • Inducing expression of human somatostatin receptor subtype 2 in tumor cells for targeted uptake of radiolabeled analogs.
  • Utilizing the sodium iodide symporter (NIS) gene transfer for free radionuclide therapy in tumor xenograft models.

Main Results:

Related Experiment Videos

  • Successful induction of high-level receptor expression and selective tumor uptake, imaging, and growth inhibition in xenograft models.
  • Therapy studies demonstrated efficacy using various radionuclides with the NIS approach in multiple tumor models.

Conclusions:

  • Gene transfer technology can significantly enhance the specificity and extent of radioligand or radionuclide localization in tumors.
  • Appropriate radionuclide selection is crucial for delivering effective cytotoxic doses, compensating for transduction inefficiencies.
  • Clinical studies are essential to validate these promising radiotargeted gene therapy strategies.